Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

Also called NCT04287387

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04287387
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04287387. Randomized; no masking; primary purpose treatment. Start 2020-03-02 (anticipated); primary completion 2021-03-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents
Condition
Type2 Diabetes Mellitus
Intervention (Drug)
Glucophage 500Mg Tablet
Intervention (Drug)
Acarbose Tablets
Intervention (Drug)
Sitagliptin tablet
Intervention (Drug)
Dapagliflozin Tablet
Intervention (Drug)
Pioglitazone Tablets
Intervention (Drug)
Glimepiride Tablets
Lead sponsor
Peking Union Medical College Hospital (class: other)
Collaborator
Chinese Academy of Sciences (class: other government)

Record details

Record id
cardio:ct-nct04287387
Content hash
5abf600c6a029e9a454c211d90744db24b8bcebe2e8cb2f3cb29e9db66a77f94